About Us

About Kiniksa

Kiniksa has an experienced team and numerous product-candidates in both clinical and preclinical development. The programs span a range of debilitating rare and specialty-focused autoinflammatory and autoimmune indications with significant unmet need.

We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.

Management Team

Sanj K. Patel

CEO & Chairman of the Board

Stephen Mahoney

President & COO

John Paolini


Carsten Boess


Chris Heberlig


Christine Maurer

SVP Program Management

Tom Beetham

Chief Legal Officer

Eben Tessari

SVP Business Development

Martina Struck

VP Regulatory Affairs

Brendan Classon

VP Research

Board of Directors

  • Felix Baker

    Lead Director

  • Stephen Biggar


  • Thomas Malley


  • Tracey McCain


  • Sanj K. Patel

    Chairman & CEO

  • Kimberly Popovits


  • Barry D. Quart


Scientific Advisory Board

  • Robert Desnick


  • Gregory Grabowski

    Chief Scientific Officer

  • Gerald Siu


  • Mark Hayes


Our History

4Q 2017

Initiates an open-label lead-in study to a planned P3 pivotal for KPL-914 in a rare cardiovascular inflammatory disease and acquires the rights to KPL-301

3Q 2017

Acquires the rights to KPL-914, KPL-045 and an exclusive option to acquire KPL-404

2Q 2017

Raises an additional $40m in capital (from new and existing investors) and begins enrollment in a P1b study in patients with cutaneous inflammatory disease with KPL-716

3Q 2016

Kiniksa acquires the world wide rights to its first program - KPL-716 - and initiates IND-enabling activities

4Q 2015

Raises $80m in committed Series A capital to focus on rapidly bringing therapies to patients who have unmet need

3Q 2015

Kiniksa is founded in Hamilton, Bermuda with its US subsidiary’s headquarters in Massachusetts